Leicester’s Hospitals Awards Deenova a Unit Dose Pharmacy Automation 15 Year Contract
2.8.2021 09:00:00 EEST | Business Wire | Press release
Deenova reported today it signed its first ever contract in the United Kingdom, and established operations in Europe’s second largest GDP health care market, with the NHS being the eight largest employer in the world. Deenova was selected by University Hospitals of Leicester NHS Trust as the best solution amongst 8 of Deenova's competitors in United Kingdom and the United States of America.
Claire Ellwood, chief pharmacist at University Hospitals of Leicester NHS Trust, said: “We’re proud to be working with Deenova to deploy the first unit dose closed loop medicines management system in the UK. Every year, we administer millions of medication doses so it’s vital our processes are as safe and efficient as possible. The partnership with Deenova will increase automation within our medication processes helping to reduce errors and wastage as well as freeing up staff time for other care and tasks. After a successful pilot, we are pleased to start planning the roll out across our three hospitals. This programme will ensure the right medicines are in the right place at the right time and will undoubtedly improve care for our patients.”
Giorgio Pavesi, Managing Director of Deenova in Italy stated: “I am extremely proud of the teamwork and dedication exhibited by our employees and those of University Hospitals of Leicester NHS Trust, proving to the health care industry the patient safety and economic advantages of Deenova´s unique Closed-Loop Medication Unit Dose management system and services, as evidenced by the report issued by the East Midlands Academic Health Science Network (AHSN) undertaking an 18 month evaluation of Deenova solutions. The published results included: 25% reduction in the consumption (and costs) of medicines; 40% reduction in the number of items held in the ward stock cupboard, 60% reduction in medicines wastage, and a reduction in missed doses due to medicine not available on wards from 10% to 1.2%, amongst other patient safety and economical benefits, leading to this award.”
Deenova plans to fulfill University Hospitals of Leicester NHS Trust’s contract award with delivery, installation and full service/support for 3 All-in-1 and 1 Acced Packaging Robots, 56 All-in-1 Station Medication Dispensing Robots, and more than 100 All-in-1 Trolleys with secure bed-side verification.
East Midlands AHSN Commercial Director, Tim Robinson, said: “A key role of AHSNs is to help build collaboration across sectors, and in particular to connect commercial innovators with the heath and care organisations that could benefit from their innovations. With this in mind, we welcome the progress made in Leicester - this is a great example of how the NHS and commercial sector can work in partnership. As well as the potential to benefit patients and generate efficiencies, we also welcome the investment into the East Midlands and the jobs this partnership will create.”
Information
Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere. Deenova’s unique, patented, and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and making the best use of staff time. Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%. Please visit www.deenova.com for additional information on its market leading solutions.
University Hospitals of Leicester NHS Trust : Every day at Leicester’s Hospitals we save lives, improve lives and usher in new life. We want to continue to improve everything that we do, so that we can achieve our vision: Caring at its best for every patient, every time. As one of the largest NHS Trusts in the country, our contribution goes beyond health; we are the largest employer in our region, we educate and train the staff of the future, push the boundaries of research and with our £1bn turnover are an economic engine for East Midlands and beyond. This is a particularly exciting time for Leicester’s Hospitals. We have been given £450m to reconfigure services and build new hospitals. This will include a new Children’s Hospital, Maternity Hospital, Treatment Centre and two new Intensive Care Units. For more information please visit: www.leicestershospitals.nhs.uk
The East Midlands Academic Health Science Network (EMAHSN) is one of 15 Academic Health Science Networks in England that operate as the innovation arm of the NHS. AHSNs bring together the NHS, universities, industry and social care to transform health and stimulate economic growth. In the East Midlands our current priorities focus on identifying and spreading innovations that respond to the COVID-19 pandemic and the recovery of services, along with priority themes including mental health, patient safety and optimising medicines. For more information please visit: www.emahsn.org.uk
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210801005037/en/
Contact information
Contacts at Deenova:
Christophe Jaffuel, Martina Buccianti
m.buccianti@deenova.com, +39 0523 785311
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fortune Media and Great Place To Work Name Experian As One Of The ‘100 Best Companies to Work For Europe’ in 2026 for Second Year8.10.2026 10:00:00 EEST | Press release
Great Place To Work® and Fortune Europe have recognised Experian as one of the Fortune 100 Best Companies to Work For™ Europe for the second-year running. The 100 Best Companies to Work For Europe list is a comprehensive recognition for business excellence and employee experience, based on Great Place To Work’s proprietary Trust Index™ Survey. Great Place To Work evaluates confidential feedback from employees, validating against HR data from participating companies. Only companies with consistently high survey responses from employees — regardless of their role, department, or status in the company — are honored with placement on the list. Eligible companies have 500 or more employees and were represented on at least one national Best Workplaces™ List in Europe. Jacky Simmonds, Chief People Officer, Experian, said: “We are thrilled to being named one of the Fortune 100 Best Companies to Work For™ in Europe for the second year in a row. It’s an incredibly proud moment for us at Experian
Value Group Brings Its Integrated Global IROPS Management Model to the World Aviation Festival8.10.2026 09:32:00 EEST | Press release
Value Group, a leading provider of integrated aviation disruption management solutions, returns to the World Aviation Festival as a Gold Sponsor, reinforcing its role in the evolution of airline disruption management. From 13 to 15 October at FIL in Lisbon, the event is one of the aviation industry’s leading international technology conferences and exhibitions, bringing together airlines, airports and travel technology companies worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261007885823/en/ Thomas Sergnese, Co-CEO & Chief Commercial Officer and Daniele Bocchieri, Co-CEO & Chief Operating Officer At stand 1-180, Value Group will showcase the evolution of its integrated disruption management model and the RUBIK digital ecosystem, demonstrating how technology, operations and governance can work together as one connected system to manage irregular operations more effectively at both global and local level. Over the p
Colruyt Group Crosses the 150 Store Milestone With Rollout of Toshiba ELERA® Self Service Store Deployments8.10.2026 08:30:00 EEST | Press release
Toshiba Global Commerce Solutions today announced the successful deployment of its ELERA® Self Service solution across 144 Colruyt Group stores: Okay, Okay City, Spar Colruyt Group and Bio-Planet. Today, 454 self-checkout systems have already been installed year-to-date across 150 stores. The project continues to expand, with an additional 51 stores planned in 2026 and further rollout in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261007465701/en/ Toshiba’s ELERA® Self Service successfully deployed across Okay, Okay City, Spar Colruyt Group and Bio-Planet stores in Belgium. The deployment was designed to support a fast, intuitive, and customer-friendly checkout experience, while maintaining the personal interaction that remains important within the convenience retail environment. Across the stores, employees remain present near the self-checkout area to assist customers whenever needed, helping ensure accessibility
Fall Clinical 2026: Galderma Presents New Three-Year Nemluvio ® Data Showing Deep and Lasting Skin Lesion and Itch Responses in Patients With Atopic Dermatitis Aged 12 and Older8.10.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new data regarding the use of Nemluvio for atopic dermatitis and prurigo nodularis to be presented at the 2026 Fall Clinical Dermatology Conference, taking place from October 08-11 in Las Vegas, United States. This includes a new post-hoc analysis from the ARCADIA LTE study showing that in adults and adolescents aged 12 and older who achieved an early response at Week 16 in the ARCADIA trial, Nemluvio achieved deep and lasting skin lesion and itch responses for up to three years.1 The data add to the growing evidence supporting the long-term efficacy of Nemluvio, underscoring Galderma's commitment to advancing the science for people living with moderate-to-severe atopic dermatitis and prurigo nodularis. “Patients and physicians increasingly expect more from treatment than temporary symptom relief. The data presented at Fall Clinical reinforce our confidence in Nemluvio's potential to deliver durable diseas
Fuji Electric Joins Helical Fusion as Strategic Investor and Official Partner as Series B Second Close Raises JPY 3.23 Billion8.10.2026 03:00:00 EEST | Press release
Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator with the goal of achieving commercially viable fusion power in the 2030s, today announced the completion of a JPY 3.23 billion (approximately USD 20.6 million) Series B second close. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261007813917/en/ Helical Fusion and new investors for the Series B 2nd close The round marks another expansion of the industrial coalition forming around Helical Fusion’s Helix Program. Fuji Electric Co., Ltd., one of Japan’s major electrical and industrial equipment manufacturers, has joined Helical Fusion as both an investor and an Official Partner of the Helix Program. Other new investors in the second close include HAZAMA ANDO CORPORATION(https://www.ad-hzm.co.jp/english/), Fujikura Ltd.(https://www.fujikura.co.jp/en/), TOKYO GAS CO., LTD.(https://www.tokyo-gas.co.jp/about/profile/index.html?wovn=en#), KKT LLC(htt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
